Skip to main content
Latest news
Browse specialties
Breast cancer Genitourinary cancers Lung & thoracic cancers
In focus
Next-generation sequencing: Emerging biomarkers in thyroid and NSCLCs ctDNA and bladder cancer: Current understanding and beyond ROS1 fusion-positive NSCLC NSCLC driver mutations: Discussing the importance of RET, ALK and ROS1 alterations in NSCLC Early-stage NSCLC management: Surgery, targeted treatment and immunotherapy ALK fusion-positive NSCLC: International approaches to management RET fusion-positive NSCLC: Informing on the use of pralsetinib for patients with RET fusion-positive, advanced NSCLC COVID-19 & cancer
Conferences
SABCS 2022 ESMO 2022 2022 ASCO Annual Meeting
About us
Medicine Matters Oncology
EXTENDED SEARCH
7 search results for:

276 

sort by |
"newest" sorts results by publication date. "most relevant" also considers factors like how often the search phrase is in the result.
  1. 08-09-2023 | Non-small-cell lung cancer | News | Article

    Add-on tumor treating fields boost metastatic NSCLC survival

    For the pivotal LUNAR trial, they recruited 276 patients with squamous or nonsquamous metastatic NSCLC who had progressed on or after platinum-based therapy and randomly assigned them to receive standard systemic therapy – investigator’s choice of ICI (nivolumab, pembrolizumab, or atezolizumab) or docetaxel – either with or without TTFields.

    Author:
    Shreeya Nanda
    Published in:
    Lancet Oncol 2023; 24 : 1002–1017 Lancet Oncol 2023; 24 : 946–947
  2. 22-11-2021 | Breast cancer | News | Article

    Cancer patterns mapped out in Li-Fraumeni syndrome

    Almost half (46.7%) of 276 individuals with complete data and a first cancer diagnosis developed second primary cancers, and the investigators estimated that the probability of developing a second cancer within 20 years of the first cancer was 66.0% for women and 45.4% for men, after accounting for death before second cancer as a competing risk.

    Author:
    Laura Cowen
    Published in:
    Lancet Oncol 2021; doi:10.1016/S1470-2045(21)00580-5
  3. 08-11-2021 | Immunotherapy | News | Article

    ICI monotherapy benefits cancer patients aged 80 and older

    The objective response rate was 32.2% among the 276 response-evaluable NSCLC patients, 39.3% among the 280 melanoma patients, and 26.2% among the 126 with genitourinary tumors.

    Author:
    Shreeya Nanda
    Published in:
    JAMA Oncol 2021; doi:10.1001/jamaoncol.2021.4960
  4. 24-06-2020 | Breast cancer | News | Article

    Mental distress high among breast cancer patients during COVID-19 peak

    In addition, 40.6% of 276 patients with a CVC had to delay flushing for over 4 weeks.

    Author:
    Laura Cowen
    Published in:
    Clin Breast Cancer 2020; doi:10.1016/j.clbc.2020.06.003
  5. 26-03-2019 | Prostate cancer | Article

    The role of multiparametric MRI in biopsy-naive prostate cancer

    Lebastchi Ah, Pinto PA. Nat Rev Urol 2019; 16: 276–277. doi:10.1038/s41585-019-0173-7 

  6. 27-02-2017 | Cutaneous melanoma | News | Article

    Immunotherapy trial eligibility criteria exclude majority of metastatic melanoma patients

    Just 45% of 276 unselected patients recorded in the metastatic section of the Danish Melanoma Database in 2014 would have been able to participate in five recent phase III clinical trials, the researchers report in the European Journal of Cancer .

    Published in:
    Eur J Cancer 2017; 74 : 89–95
  7. 03-06-2016 | Chronic myeloid leukemia | Article

    European LeukemiaNet recommendations for the management and avoidance of adverse events of treatment in chronic myeloid leukaemia

    This article provides the European LeukemiaNet recommendations for managing and avoiding adverse events in patients receiving tyrosine kinase inhibitors for chronic myeloid leukemia. Leukemia  2016; 30: 1648–1671. doi:10.1038/leu.2016.104

    Author:
    J L Steegmann, M Baccarani, M Breccia, L F Casado, V García-Gutiérrez, A Hochhaus, D-W Kim, T D Kim, H J Khoury, P Le Coutre, J Mayer, D Milojkovic, K Porkka, D Rea, G Rosti, S Saussele, R Hehlmann, R E Clark
  • 1

Filter search results

Search Operators:

„ ... ... “ Finds documents with exactly this word group, in exactly this word order and spelling (e.g., "employer branding").
AND Finds documents with both search terms (e.g., sales AND bonus).
OR Finds documents with one or the other search term (e.g., porsche OR volkswagen).
Blank Space Finds documents with all search terms. Blank space is understood as AND (e.g., man robot production).
NOT Finds documents with no appearance of the word behind NOT (e.g., ford NOT "harrison ford").
COUNT(...)>n Finds documents where the search term is mentioned at least "n" times."n" may be any number (e.g., COUNT(gear)>8).
NEAR(..., ..., ) Finds documents with both search terms in any word order, permitting "n" words as a maximum distance between them. Best choose between 15 and 30 (e.g., NEAR(recruit, professionals, 20)).
* Finds documents with the search term in word versions or composites. The star * marks whether you wish them BEFORE, BEHIND, or BEFORE and BEHIND the search term (e.g., lightweight*, *lightweight, *lightweight*).
? Finds documents with the search termn in different spellings."?" allows only one character (e.g., organi?ation).
& + - Special characters are understood as AND (e.g., Miller Bros. & Sons).

You can use operators in your search query to narrow down your results even more.

Tap the operator, or hover the mouse pointer over it, to read more about how it works.